Market Brief

The articles are produced in Chinese only.

Author

倪國權先生 (Alex Ni)
助理經理

曾任職鋼材交易員及廣告公司主任,所以特別喜歡研究資源類及消費類股票。歡迎來電賜教或交流心得。
Phone:
22776779

UMP HEALTHCARE HOLDINGS LTD. (722)

Friday, March 25, 2022 Views4666

Commentary:

Stock:

UMP Healthcare Holdings Ltd.

 

1 Month H/L:

0.86 – 0.75

Stock Code:

772.HK

 

52 week H/L:

1.212 – 0.622

Market Cap.:

HKD 634.133M

 

Listing date:

27/11/2015

Stock Outstanding:

792,666,555 shares

 

Listing price:

2.06

P/E (TTM):

17.467x

 

Chairman & CEO:

Dr. Sun Yiu Kwong

Dividend:

0.038

 

Major Shareholdes:

1. Mr. Sun Yiu Kwong – 35.52%

Dividend Yield:

4.75%

 

 

2. Chow Tai Fook (Holding)Ltd – 15.04%

 

 

 

 

3. China Resources Medical Holdings Co. Ltd. - 11.99%

 

           Established in 1990, UMP health care is a healthcare solution provider operating in Hong Kong as well as Macau and Mainland China. The company's business consist of: 1. Hong Kong & Macau corporate healthcare solutions, 2. Clincal healthcare services, and 3. Mainland China healthcare business.

           The company released its interim result on the 24th of February, the table below briefly summarised the company's performance:

Business segment

Business description

Remarks

Hong Kong & Macau Corporate healthcare solutions

Tailored healthcare plan to corporate customers, for example, insurance companies, whom their policy holders can use the services.

Also, corporations can contract the company to provide healthcare services plan to its employees.

 

Revenue increased by 1.8% from HK$122.3 million for 1HFY2021 to HK$124.5 miilion. Contributions mainly attributed by Medical services, due to number of visits from patients seeking Medical services increased.

Hong Kong & Macau Clinical healthcare services

To provide service to self-paid patients, areas include:

- Medical: general practice services.

- Specialist service/consultation: cover 18 different specialities.

- Dental: dental care, dental check up. Also provide services such as dental implants.

- Auxiliary: Physiotherapy, vision & eye care.

- Medical imaging

- Laboratory services.

Revenue of this segment increased by 28.1% from HK$213.1 million for 1HFY2021 to HK$273.0 million for 1HFY2022. The increase mainly due to health check-ups and the medical imaging as well as laborator business.

 

One point to note that specialist business as well as medical imaging business had been of the main contribution to this line of business, according to the group M&A analysis in 2021 annual report.

 

 

 

Mainland China healthcare business

Businesses include:

- Healthcare check-up business

- Company owned clinic to provide outpatient services

Revenue of this business line incresed by 29.9% from HK$17.5 million to HK$22.7 million.

 

 

* Part of the operation that engaged in corporation healthcare solutions as well as professional training of doctors and nurses in mainland China was disposed last year.

Source: Company's annual reports and interim reports

 

           The company's revenue had been growing steadily for the past seven years, the drop in year 2020 was attributed to the pandmeic. The growth was subsequently picked in year 2021. The company continued to re-adjust their business strategies through re-organising (Mainland China business) and acquistions (Medical imaging business etc). We expect that the company may continue to expand the medical imaging, laboratary services as well as specialist services since these areas had been one of the main revenue driver for the past few years.

 

This report is produced and is being distributed in Hong Kong by Phillip Securities Group with the Securities and Futures Commission (“SFC”) licence under Phillip Securities (HK) LTD and/ or Phillip Commodities (HK) LTD (“Phillip”). Information contained herein is based on sources that Phillip believed to be accurate. Phillip does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The information is for informative purposes only and is not intended to or create/induce the creation of any binding legal relations. The information provided do not constitute investment advice, solicitation, purchase or sell any investment product(s). Investments are subject to investment risks including possible loss of the principal amount invested. You should refer to your Financial Advisor for investment advice based on your investment experience, financial situation, any of your particular needs and risk preference. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk. Phillip (or employees) may have positions/ interests in relevant investment products. Phillip (or one of its affiliates) may from time to time provide services for, or solicit services or other business from, any company mentioned in this report. The above information is owned by Phillip and protected by copyright and intellectual property Laws. It may not be reproduced, distributed or published for any purpose without prior written consent from Phillip.
Top of Page
Contact Us
Please contact your account executive or call us now.
Research Department
Tel : (852) 2277 6846
Fax : (852) 2277 6565
Email : businessenquiry@phillip.com.hk

Enquiry & Support
Branches
The Complaint Procedures
About Us
Phillip Securities Group
Join Us
Phillip Network
Phillip Post
Phillip Channel
Latest Promotion
E-Check
Login
Investor Notes
Free Subscribe
Contact Us